April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Long-term treatment outcome of anti-VEGF therapy for myopic choroidal neovascularization
Author Affiliations & Notes
  • Koji Honda
    resident, Tokyo, Japan
  • Asako Ogawa
    resident, Tokyo, Japan
  • Ryo Obata
    resident, Tokyo, Japan
  • Yasuo Yanagi
    resident, Tokyo, Japan
  • Footnotes
    Commercial Relationships Koji Honda, None; Asako Ogawa, None; Ryo Obata, None; Yasuo Yanagi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4979. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Koji Honda, Asako Ogawa, Ryo Obata, Yasuo Yanagi; Long-term treatment outcome of anti-VEGF therapy for myopic choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4979.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Purpose: To investigate the long-term treatment outcome of anti-VEGF therapy for myopic CNV (mCNV).

Methods: Methods: In this retrospective study, 26 eyes of 26 patients with mCNV who underwent intravitreal injection of 1.25 mg bevacizumab. All eyes underwent best corrected visual acuity (BCVA) measurement before the treatment, and 1,2 and 3 years after the injection. Twelve eyes completed observations up to 5 years. The main outcome measures were changes in BCVA from the baseline.

Results: Results: Mean patients’ age was 61.4±13.1 years old. At baseline, mean BCVA was 0.63±0.43 logMAR unit . Change in the BCVA in the 1,2 and 3 years were -0.14±0.29, -0.15±0.39 and -0.08±0.35. At four and five years, change in BCVA was -0.05±0.36 and 0.03±0.48. Proportions of patients that lost more than three line were 15.4, 11.5, 23.1, 30 and 41%, at 1, 2, 3, 4 and 5 years, respectively. Study eyes received a mean of 1.35, 0.38, 0.15, 0.25 and 0 injections at year 1,2,3,4 and 5. Chorioretinal atrophy was predominant findings that results in poor visual outcome.

Conclusions: Conclusions: Even with anti-VEGF therapy, patients with mCNV remain at long-term risk of visual decline due to chorioretinal atrophy.

Keywords: 453 choroid: neovascularization • 605 myopia  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.